Syndax Pharmaceuticals Inc.

NASDAQ: SNDX
Share price (1/3/25): $14.37
Market cap (1/3/25): $1.227 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

ended 09/30/23 Q3

Prospectuses and Registrations Filter

Automatic shelf registration

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Wellington Management Group Llp

State Street Corporation

News Filter

Change in Directors, Officers or Compensation

Announces FDA Approval of Revuforj® (Revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients With Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

Announces Positive Pivotal Topline Results From Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

Reports Third Quarter 2024 Financial Results and Provides Business Update

Material Definitive Agreement

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission